Immune to Cancer: The CRI Blog
-
Colorectal Cancer Awareness Month: How Immunotherapy Offers Hope for the Future
March is Colorectal Cancer Awareness Month, and the need for a spotlight on this disease is as…
-
Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer
Nivolumab improves survival in patients with advanced stomach cancer.
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints
The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.
-
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
New hope now exists for patients with advanced head and neck cancer.
-
ASCO 2016 Update: Immunotherapy & Melanoma: The Path to Progress
Improved approaches for treating patients with melanoma.
-
ASCO 2016 Update: Checkpoint Immunotherapy Advances in Solid Cancers
New insights, approaches to improve outcomes in melanoma, kidney, bladder, and colorectal cancers.
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.